1. Home
  2. TALK vs TBPH Comparison

TALK vs TBPH Comparison

Compare TALK & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Talkspace Inc.

TALK

Talkspace Inc.

HOLD

Current Price

$5.17

Market Cap

788.5M

Sector

Health Care

ML Signal

HOLD

Logo Theravance Biopharma Inc.

TBPH

Theravance Biopharma Inc.

HOLD

Current Price

$16.43

Market Cap

824.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TALK
TBPH
Founded
2012
2013
Country
United States
United States
Employees
521
N/A
Industry
Medical/Nursing Services
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
788.5M
824.9M
IPO Year
N/A
2013

Fundamental Metrics

Financial Performance
Metric
TALK
TBPH
Price
$5.17
$16.43
Analyst Decision
Buy
Buy
Analyst Count
6
6
Target Price
$6.42
$17.80
AVG Volume (30 Days)
7.9M
559.9K
Earning Date
05-05-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
279.13
EPS
N/A
2.06
Revenue
N/A
$15,386,000.00
Revenue This Year
$26.02
$9.51
Revenue Next Year
$21.24
N/A
P/E Ratio
$155.55
$7.82
Revenue Growth
N/A
N/A
52 Week Low
$2.22
$8.09
52 Week High
$5.20
$21.03

Technical Indicators

Market Signals
Indicator
TALK
TBPH
Relative Strength Index (RSI) 64.20 57.81
Support Level $4.59 $13.41
Resistance Level $5.19 $19.04
Average True Range (ATR) 0.02 0.53
MACD -0.03 0.37
Stochastic Oscillator 56.25 95.82

Price Performance

Historical Comparison
TALK
TBPH

About TALK Talkspace Inc.

Talkspace Inc is a behavioral healthcare company offering access to licensed therapists, psychologists, and psychiatrists through its technology platform. It serves clients including health plans, enterprises, and individual subscribers. Therapists address various mental health conditions, while psychiatrists cater to a higher acuity demographic. Revenue stems from payor and direct-to-enterprise clients, with contracts lasting one to three years. The majority of the Company's operations and revenues are based in the United States.

About TBPH Theravance Biopharma Inc.

Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.

Share on Social Networks: